- Cisplatin is the cornerstone systemic agent in locally advanced head and neck squamous cell carcinoma (HNSCC)
- Concurrent Chemoradiation (Definitive Setting):
- Standard of care for locally advanced, unresectable HNSCC (or when organ preservation is desired, e.g., larynx, oropharynx).
- High-dose cisplatin: 100 mg/m² IV every 3 weeks × 3 cycles concurrent with radiation therapy.
- Alternative (for toxicity or frailty): weekly low-dose cisplatin (30–40 mg/m²).
- Evidence: Landmark trials (EORTC, RTOG) showed improved overall survival and locoregional control when cisplatin was added to radiation versus radiation alone.
2. Adjuvant (Postoperative) Chemoradiation
- Indicated for high-risk features after surgery:
- Positive margins
- Extracapsular nodal extension
- High-dose cisplatin concurrent with adjuvant radiation reduces recurrence and improves survival (EORTC 22931, RTOG 9501).
3. Palliative / Metastatic Disease
- Cisplatin combined with 5-FU or taxanes, historically standard in recurrent/metastatic disease.
- More recently, cisplatin used in combination with immune checkpoint inhibitors (e.g., pembrolizumab, nivolumab) in first-line regimens (KEYNOTE-048).
Key Points for Clinical Use
- Highly emetogenic → requires aggressive antiemetic prophylaxis (NK1 antagonist + 5HT3 antagonist + dexamethasone).
- Toxicities: nephrotoxicity, ototoxicity, neurotoxicity, myelosuppression.
- Alternative for cisplatin-ineligible patients: carboplatin ± 5-FU, or immunotherapy-based regimens.
✅ Summary: Cisplatin exerts its anti-cancer effects by forming DNA crosslinks that trigger apoptosis. In head and neck cancer, it is the backbone of definitive chemoradiation, adjuvant chemoradiation for high-risk patients, and palliative regimens. High-dose cisplatin remains the gold standard for fit patients, with weekly dosing or alternative agents reserved for those with comorbidities.
Would you like me to also prepare a slide-ready summary table comparing cisplatin 100 mg/m² q3w vs 40 mg/m² weekly in head and neck chemoradiation (efficacy, toxicity, compliance)? That’s a common journal club/board question.
You said:
mechanism of acton
ChatGPT said:
Here’s a clear explanation of the mechanism of action of cisplatin (the essence, without the broader oncology indications):
Mechanism of Action of Cisplatin
- Cell Entry
- Cisplatin enters tumor cells by passive diffusion and through membrane transporters (notably copper transporters such as CTR1).
- Activation (Aquation)
- In the bloodstream, cisplatin is relatively stable because of high chloride concentrations.
- Once inside the cell (where chloride concentration is lower), cisplatin undergoes aquation: its chloride ligands are replaced by water molecules, creating a highly reactive, positively charged complex.
- DNA Interaction
- The activated cisplatin binds strongly to guanine and adenine bases in DNA.
- It forms:
- Intrastrand crosslinks (most common: between adjacent guanines or guanine–adenine)
- Interstrand crosslinks
- DNA–protein crosslinks
- Cellular Consequences
- These DNA adducts distort the double helix, blocking replication and transcription.
- DNA damage response pathways are activated (p53-dependent and independent).
- When repair is unsuccessful, this leads to cell-cycle arrest and apoptosis (programmed cell death).
- Other Effects
- Cisplatin can also interact with RNA and proteins, contributing to its cytotoxicity.
- Oxidative stress and mitochondrial dysfunction also play a role in cell death.
✅ In short: Cisplatin kills cancer cells by forming DNA crosslinks that prevent proper replication and transcription, ultimately triggering apoptosis.
Cisplatin is the cornerstone systemic agent in locally advanced head and neck squamous cell carcinoma (HNSCC).
1. Concurrent Chemoradiation (Definitive Setting)
- Standard of care for locally advanced, unresectable HNSCC (or when organ preservation is desired, e.g., larynx, oropharynx).
- High-dose cisplatin: 100 mg/m² IV every 3 weeks × 3 cycles concurrent with radiation therapy.
- Alternative (for toxicity or frailty): weekly low-dose cisplatin (30–40 mg/m²).
- Evidence: Landmark trials (EORTC, RTOG) showed improved overall survival and locoregional control when cisplatin was added to radiation versus radiation alone.
2. Adjuvant (Postoperative) Chemoradiation
- Indicated for high-risk features after surgery:
- Positive margins
- Extracapsular nodal extension
- High-dose cisplatin concurrent with adjuvant radiation reduces recurrence and improves survival (EORTC 22931, RTOG 9501).
3. Palliative / Metastatic Disease
- Cisplatin combined with 5-FU or taxanes, historically standard in recurrent/metastatic disease.
- More recently, cisplatin used in combination with immune checkpoint inhibitors (e.g., pembrolizumab, nivolumab) in first-line regimens (KEYNOTE-048).
Key Points for Clinical Use
- Highly emetogenic → requires aggressive antiemetic prophylaxis (NK1 antagonist + 5HT3 antagonist + dexamethasone).
- Toxicities: nephrotoxicity, ototoxicity, neurotoxicity, myelosuppression.
- Alternative for cisplatin-ineligible patients: carboplatin ± 5-FU, or immunotherapy-based regimens.
✅ Summary: Cisplatin exerts its anti-cancer effects by forming DNA crosslinks that trigger apoptosis. In head and neck cancer, it is the backbone of definitive chemoradiation, adjuvant chemoradiation for high-risk patients, and palliative regimens. High-dose cisplatin remains the gold standard for fit patients, with weekly dosing or alternative agents reserved for those with comorbidities.
Would you like me to also prepare a slide-ready summary table comparing cisplatin 100 mg/m² q3w vs 40 mg/m² weekly in head and neck chemoradiation (efficacy, toxicity, compliance)? That’s a common journal club/board question.
You said:
mechanism of acton
ChatGPT said:
Here’s a clear explanation of the mechanism of action of cisplatin (the essence, without the broader oncology indications):
Mechanism of Action of Cisplatin
- Cell Entry
- Cisplatin enters tumor cells by passive diffusion and through membrane transporters (notably copper transporters such as CTR1).
- Activation (Aquation)
- In the bloodstream, cisplatin is relatively stable because of high chloride concentrations.
- Once inside the cell (where chloride concentration is lower), cisplatin undergoes aquation: its chloride ligands are replaced by water molecules, creating a highly reactive, positively charged complex.
- DNA Interaction
- The activated cisplatin binds strongly to guanine and adenine bases in DNA.
- It forms:
- Intrastrand crosslinks (most common: between adjacent guanines or guanine–adenine)
- Interstrand crosslinks
- DNA–protein crosslinks
- Cellular Consequences
- These DNA adducts distort the double helix, blocking replication and transcription.
- DNA damage response pathways are activated (p53-dependent and independent).
- When repair is unsuccessful, this leads to cell-cycle arrest and apoptosis (programmed cell death).
- Other Effects
- Cisplatin can also interact with RNA and proteins, contributing to its cytotoxicity.
- Oxidative stress and mitochondrial dysfunction also play a role in cell death.
✅ In short: Cisplatin kills cancer cells by forming DNA crosslinks that prevent proper replication and transcription, ultimately triggering apoptosis.
